Safety and tolerability of human placenta-derived cells (PDA001) in treatment-resistant crohn's disease: A phase 1 study

Inflammatory Bowel Diseases

Volumn 19, Issue 4, 2013, Pages 754-760

  Mayer, Lloyd ^a   Pandak, William M ^b   Melmed, Gil Y ^c   Hanauer, Stephen B ^d   Johnson, Kristine ^e   Payne, Denise ^e   Faleck, Herbert ^e   Hariri, Robert J ^e   Fischkoff, Steven A ^e  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^e CELGENE CORPORATION   (United States)

Author keywords

Biologic therapies; Cellular therapies; Crohn's disease; Immunomodulators

Indexed keywords

CENPLACEL L;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE SEVERITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; HUMAN PLACENTA DERIVED CELL; INJECTION SITE REACTION; LOW DRUG DOSE; MALE; NAUSEA; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL; PLACENTA; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELLS, CULTURED; CROHN DISEASE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PLACENTA; PREGNANCY; QUESTIONNAIRES; REMISSION INDUCTION; SALVAGE THERAPY; TISSUE THERAPY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84876367679     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e31827f27df     Document Type: Article

References (23)

1. Mayer L. Evolving paradigms in the pathogenesis of IBD. J Gastroenterol. 2010;45:9-16.
2. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3:521-533.
3. Bamias G, Cominelli F. Novel strategies to attenuate immune activation in Crohn's disease. Curr Opin Pharmacol. 2006;6:401-407.
4. Triantafillidis JK, Merikas E, Georgopoulos F. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther. 2011;5:185-210.
5. Podolsky D. Inflammatory bowel disease. N Engl J Med. 2002;347: 417-429.
6. Kucharzik T, Maaser C, Lugering A, et al. Recent understanding of IBD pathogenesis: implications for future therapies. Inflamm Bowel Dis. 2006; 12:1068-1083.
7. Singh UP, Singh NP, Singh B, et al. Stem cells as potential therapeutic targets for inflammatory bowel disease. Front Biosci (Schol Ed). 2010;2: 993-1008.
8. Lanzoni G, Roda G, Belluzzi A, et al. Inflammatory bowel disease: moving toward a stem cell-based therapy. World J Gastroenterol. 2008;14:4616-4626.
9. García-Bosch O, Ricart E, Panés J. Review article: stem cell therapies for inflammatory bowel disease-efficacy and safety. Aliment Pharmacol Ther. 2010;32:939-952.
10. Paludan C, Harbacheuski R, Murray R, et al. Placenta derived stem cells (PDAC) suppress the allo-MLR and the EBV regression assay. Blood. 2006;108:1737.
11. Li X, Ling W, Pennisi A, et al. Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone. Stem Cells. 2011;29:263-273.
12. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
13. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989;96: 804-810.
14. Hlavaty T, Persoons P, Vermeire S, et al. Values of inflammatory bowel disease questionnaire in Crohn's disease. Inflamm Bowel Dis. 2006;12: 199-204.
15. Hanauer S, Sandborn W, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333.
16. Higgins P, Schwartz M, Mapili J, et al. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut. 2005;54:782-788.
17. Irvine E, Greenberg G, Feagan B, et al. Quality of life rapidly improves with budesonide therapy for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. Inflamm Bowel Dis. 2000;6:181-187.
18. European Group for Blood and Marrow Transplantation. ASTIC autologous stem cell transplantation for Crohn's disease [ClinTrials.gov Web site]. October 14, 2010. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00297193? term1/4ASTIC+crohn%27s&rank1/41. Accessed February 3, 2012.
19. Zuk PA, Zhu M, Ashjian P, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 2002;13:4279-4295.
20. García-Olmo D, García-Arranz M, García LG, et al. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn's disease: a new cell-based therapy. Int J Colorectal Dis. 2003;18:451-454.
21. Garcia-Olmo D, Garcia-Arranz M, Herreros D, et al. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005;48:1416-1423.
22. Onken JE, Gallup D, Hanson J, et al. Successful outpatient treatment of refractory Crohn's disease using adult mesenchymal stem cells. Presented at: ACG 2006 Final Program Book, October 20-25, 2006, Las Vegas, Nevada. 2006:121.
23. Celgene Corporation. A multi-center study to evaluate the safety and efficacy of intravenous infusion of human placenta-derived cells (PDA001) for the treatment of adults with moderate-to-severe Crohn's disease [ClinTrials.gov Web site]. October 11, 2011. Available at: http://www.clinicaltrials.gov/ct2/ show/NCT01155362?term1/4celgene+crohn%27s&rank1/41. Accessed February 3, 2012.